306 related articles for article (PubMed ID: 17451279)
21. Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.
Ejskjaer N; Rasmussen M; Kamp N; Lindholm A; Christiansen JS
Diabetes Obes Metab; 2003 Nov; 5(6):438-45. PubMed ID: 14617230
[TBL] [Abstract][Full Text] [Related]
22. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
[TBL] [Abstract][Full Text] [Related]
23. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
25. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
[TBL] [Abstract][Full Text] [Related]
26. Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy.
Heise T; Heinemann L; Hövelmann U; Brauns B; Nosek L; Haahr HL; Olsen KJ
Diabetes Care; 2009 Aug; 32(8):1431-3. PubMed ID: 19487640
[TBL] [Abstract][Full Text] [Related]
27. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
28. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
Gumprecht J; Benroubi M; Borzi V; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y; Ligthelm R; Valensi P;
Int J Clin Pract; 2009 Jun; 63(6):966-72. PubMed ID: 19504715
[TBL] [Abstract][Full Text] [Related]
29. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
30. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
Hussein Z; Lim-Abrahan MA; Jain AB; Goh SY; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
[TBL] [Abstract][Full Text] [Related]
31. Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results.
Nobels F; D'Hooge D; Crenier L
Curr Med Res Opin; 2012 Jun; 28(6):1017-26. PubMed ID: 22612579
[TBL] [Abstract][Full Text] [Related]
32. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes.
Hermansen K; Vaaler S; Madsbad S; Dalgaard M; Zander M; Begtrup K; Soendergaard K
Metabolism; 2002 Jul; 51(7):896-900. PubMed ID: 12077738
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
[TBL] [Abstract][Full Text] [Related]
34. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
[TBL] [Abstract][Full Text] [Related]
35. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.
Moses AC; Raskin P; Khutoryansky N
Diabet Med; 2008 Feb; 25(2):200-5. PubMed ID: 18290862
[TBL] [Abstract][Full Text] [Related]
36. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
Dashora U; Ashwell SG; Home PD
Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
[TBL] [Abstract][Full Text] [Related]
37. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.
Liebl A; Prusty V; Valensi P; Kawamori R; Christiansen JS; Palmer AJ; Balschmidt P; Ligthelm R; Mohan V
Drugs; 2012 Jul; 72(11):1495-520. PubMed ID: 22818015
[TBL] [Abstract][Full Text] [Related]
38. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
[TBL] [Abstract][Full Text] [Related]
39. Premixed insulin analogues for the treatment of diabetes mellitus.
Garber AJ
Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
[TBL] [Abstract][Full Text] [Related]
40. Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes.
Shah S; Das AK; Kumar A; Unnikrishnan AG; Kalra S; Baruah MP; Ganapathi B; Sahay RK
Adv Ther; 2009 Mar; 26(3):325-35. PubMed ID: 19252828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
